# Federal Register #2026-23413

FDA drug-approval notices and IHS Fiscal Year 2027 CHEF threshold

**Buyer:** U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER)
**Posted:** November 18, 2026
**Respond By:** December 18, 2026
**Identifier:** 2026-23413

This notice combines FDA drug-approval actions with an Indian Health Service CHEF threshold announcement.
- **Agencies:** U.S. Department of Health and Human Services (HHS), including the Food and Drug Administration (FDA) and its Center for Drug Evaluation and Research (CDER); Indian Health Service (IHS).
- **FDA products and actions:**
  - BROMFED-DM syrup (ANDA 088811), with brompheniramine maleate, dextromethorphan hydrobromide, and pseudoephedrine hydrochloride, is listed as discontinued; FDA determined it was not withdrawn for safety or effectiveness reasons. Additional qualifying ANDAs may be approved.
  - FDA proposes withdrawing approval of **Salerno Pharmaceuticals’ Flolipid suspension** (NDA 206679; 20 mg/5 mL and 40 mg/5 mL) because required annual reports were repeatedly not filed. The NDA holder may request a hearing, and interested parties may submit comments.
- **IHS:** The Fiscal Year 2027 CHEF threshold is $20,258.
- **Procurement status:** This is a regulatory and program-threshold notice, not a solicitation; no products or services are being purchased.

### Description

The FDA proposes to withdraw approval of NDA 206679 for Flolipid suspension in 20 mg/5 mL and 40 mg/5 mL strengths. The proposal is based on Salerno Pharmaceuticals repeatedly failing to submit required annual reports and not responding to the agency’s request for those reports. The NDA holder may request a hearing by December 18, 2026, and must submit supporting data and analyses by January 19, 2027. Electronic or written comments are also due January 19, 2027.

[View original listing](https://www.federalregister.gov/documents/2026/11/18/2026-23413/salerno-pharmaceuticals-proposal-to-withdraw-approval-of-a-new-drug-application-for-flolipid)
